| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2016: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2015: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
|
|---|
| Outline of Final Research Achievements |
It has been demonstrated that bone fracture rate is elevated in type 2 diabetes. However, the mechanism was not fully elucidated. In this study, we investigated the involvement of altered osteoclast precursor on bone fragility in type 2 diabetes. Cortical thickness of distal radius and monocyte subsets were measured in type 2 diabetes. It revealed that CD16+ monocytes presented osteoclast marker. The rate of CD16+ monocytes is increased in lower cortical thickness group. Furthermore, the rate of CD16+ monocytes is negatively correlated with cortical thickness. The rate of CD16+ monocytes is also an independent risk factor to cortical thickness. This study elucidated possible involvement of altered proportion of CD16+ monocyte, which is one of the osteoclast precursors, on bone fragility in type 2 diabetes.
|
